Taieb, Julien, Seufferlein, Thomas, Reni, Michele, Palmer, Daniel H 
ORCID: 0000-0002-7147-5703, Bridgewater, John A, Cubillo, Antonio, Prager, Gerald W, Vermeire, Alice, Hedouin-Biville, Fabienne, Teng, Zhaoyang et al (show 1 more authors)
(2023)
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
BMC CANCER, 23 (1).
877-.
Abstract
<h4>Background</h4>Real-world data on treatment patterns/outcomes for metastatic pancreatic cancer (mPAC) are limited. This study aims to assess real-world treatment patterns, survival outcomes, and prognostic/predictive factors in patients with mPAC.<h4>Methods</h4>Retrospective, observational, chart-review involving medical oncologists and gastroenterologists from five European countries. Physicians reported information on disease and patient characteristics, diagnosis, and treatment for patients diagnosed with mPAC from January-October 2016. Outcomes included median progression-free survival (mPFS), median overall survival (mOS), and the impact of baseline performance status on survival. Univariate/multivariate regression analyses were undertaken to identify prognostic/predictive factors.<h4>Results</h4>Three hundred four physicians and 3432 patients were included. First-line therapies included modified (m)FOLFIRINOX (28.4%), gemcitabine + nab-paclitaxel (28.0%), and gemcitabine monotherapy (23.0%). Frequent second-line therapies were gemcitabine monotherapy (25.0%), fluorouracil (5-FU) + oxaliplatin (21.8%), and gemcitabine + nab-paclitaxel (16.7%). Most frequent first- to second-line treatment sequences were gemcitabine + nab-paclitaxel followed by fluoropyrimidine combinations. Longest unadjusted estimated mOS was observed with (m)FOLFIRINOX followed by gemcitabine-based combinations (19.1 months). Multivariate analysis identified significant prognostic/predictive factors for OS and PFS including performance status and carbohydrate antigen 19-9 (CA 19-9) levels.<h4>Conclusions</h4>Treatment and treatment sequences were generally in accordance with guidelines at the time of the study. Identification of prognostic/predictive factors for survival may help inform the individualised management of mPAC patients in the future.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Metastatic, Pancreatic cancer, Prognostic factors, Real-world data, Survival |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 06 Feb 2024 11:10 |
| Last Modified: | 06 Feb 2024 11:10 |
| DOI: | 10.1186/s12885-023-11377-1 |
| Open Access URL: | https://doi.org/10.1186/s12885-023-11377-1 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3178503 |
Dimensions
Dimensions
